Mutational Load is Only One Piece of the Immunotherapy PuzzleTargeted OncologyAs immunotherapies become a greater part of the treatment paradigm of various cancers, researchers are spending more time developing ways to determine which patients will res… Continue reading
Immunotherapy Making Its Mark on Head and Neck CancerTargeted OncologyFollowing the approval of 2 immunotherapy agents, pembrolizumab (Keytruda) and nivolumab (Opdivo) for the treatment of patients with head and neck cancer (HNC) over the last 6 months… Continue reading
|
Anti-BCMA CAR T-Cell Therapy Approaches 80% Response Rate in Multiple Myeloma
Targeted Oncology An investigational anti–B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy demonstrated an objective response rate (ORR) of 78% in patients with relapsed/refractory multiple myeloma, according to interim findings of a phase … |
WEAR |
Plasma and stem cells: The future of regenerative medicine
WEAR (WEAR) — Blood platelet injections and stem cell treatments may sound like the future, but physicians at the Andrews Institute are already practicing these forms of regenerative medicine. Weight lifting mixed with normal wear and tear left Howie … |
WEAR |
Plasma and stem cells: The future of regenerative medicine
WEAR (WEAR) — Blood platelet injections and stem cell treatments may sound like the future, but physicians at the Andrews Institute are already practicing these forms of regenerative medicine. Weight lifting mixed with normal wear and tear left Howie … |